These mutant-specific KRAS-targeted drugs, including Sotorasib, Adagrasib, and MRTX1133, provide new hope for patients suffering from highly malignant tumors driven by KRAS mutations such as pancreatic cancer, lung cancer, and colon cancer. This evidence concerns the gene KRAS and lung carcinoma.